New combo drug study seeks clues to fight solid tumors

NCT ID NCT06651593

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will receive the treatment, and the main goal is to track safety and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Md Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact